Want to see ANAB full AI Analyst Report?
Top Page
AnaptysBio
(NASDAQ:ANAB)
Select Model
Select Model
Rating:49Neutral
Price Target:
$55.00
▼(-5.17% Downside)
Action:Reiterated
Date:08/12/26
ANAB scores below average mainly due to fragile fundamentals: TTM revenue/cash flow cooled after a strong 2025 and the balance sheet cushion weakened with higher leverage and lower equity, while KPIs indicate dependence on royalty/licensing income and ongoing Biopharma losses. Technical signals are neutral-to-soft (negative MACD, RSI near 50), and valuation provides limited support given negative earnings and no dividend.
Positive Factors
Proprietary antibody discovery platform
AnaptysBio’s core platform provides durable R&D leverage: proprietary antibody discovery and engineering supports multiple internal programs and partnerable assets. Platform-based innovation increases the probability of repeatable deals, scales knowledge transfer across programs, and sustains long-term pipeline optionality.
Negative Factors
Weakened balance sheet and higher leverage
Trailing-period deterioration pushed debt-to-equity above 1x and equity declined sharply, reducing the balance sheet cushion. Higher leverage constrains financial flexibility, raises refinancing and covenant risk, and makes the company more sensitive to timing of milestone receipts and adverse cash shocks over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary antibody discovery platform
AnaptysBio’s core platform provides durable R&D leverage: proprietary antibody discovery and engineering supports multiple internal programs and partnerable assets. Platform-based innovation increases the probability of repeatable deals, scales knowledge transfer across programs, and sustains long-term pipeline optionality.
Read all positive factors
AnaptysBio Key Performance Indicators (KPIs)
AnaptysBio (ANAB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.73B
Dividend YieldN/A
Average Volume (3M)738.88K
Price to Earnings (P/E)―
Beta (1Y)0.92
Revenue Growth107.73%
EPS Growth82.33%
CountryUS
Employees104
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.87
Shares Outstanding29,608,480
10 Day Avg. Volume927,720
30 Day Avg. Volume738,876
Financial Highlights & Ratios
PEG Ratio0.77
Price to Book (P/B)24.14
Price to Sales (P/S)3.83
P/FCF Ratio45.80
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$84.75Price Target Upside46.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.07
Revenue Forecast (FY)$65.41M
AnaptysBio Business Overview & Revenue Model
Company Description
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete...
How the Company Makes Money
AnaptysBio makes money primarily through collaboration and licensing arrangements rather than product sales (it is a clinical-stage company and does not consistently generate revenue from commercialized products). Key revenue streams typically inc...
AnaptysBio Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
45
Neutral
Cash Flow
57
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 232.39M | 234.60M | 91.28M | 17.16M | 10.29M | 63.17M |
| Gross Profit | 270.54M | 232.18M | -72.56M | -115.13M | -78.51M | -35.32M |
| EBITDA | 58.49M | 69.25M | -92.74M | -156.42M | -105.26M | -55.71M |
| Net Income | -26.79M | -13.23M | -145.23M | -163.62M | -128.72M | -57.80M |
Balance Sheet | ||||||
| Total Assets | 329.68M | 364.39M | 483.83M | 452.39M | 610.38M | 643.07M |
| Cash, Cash Equivalents and Short-Term Investments | 286.45M | 311.64M | 385.37M | 390.90M | 441.24M | 548.10M |
| Total Debt | 277.36M | 14.11M | 369.46M | 17.81M | 19.45M | 20.95M |
| Total Liabilities | 316.94M | 327.19M | 412.97M | 364.29M | 348.28M | 286.64M |
| Stockholders Equity | 12.75M | 37.21M | 70.87M | 88.10M | 262.10M | 356.43M |
Cash Flow | ||||||
| Free Cash Flow | 4.41M | 19.61M | -135.69M | -121.61M | -73.95M | -47.29M |
| Operating Cash Flow | 4.48M | 19.70M | -135.34M | -120.80M | -73.59M | -45.92M |
| Investing Cash Flow | 248.17M | 228.03M | 95.40M | 144.75M | -394.85M | 38.84M |
| Financing Cash Flow | -102.81M | -132.61M | 127.05M | -59.30M | 44.02M | 252.30M |
AnaptysBio Technical Analysis
Positive
58.00
Price Trends
58.45
Negative
57.37
Positive
45.27
Positive
Market Momentum
0.37
Negative
51.89
Neutral
59.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANAB, the sentiment is Positive. The current price of 58 is above the 20-day moving average (MA) of 56.78, below the 50-day MA of 58.45, and above the 200-day MA of 45.27, indicating a neutral trend. The MACD of 0.37 indicates Negative momentum. The RSI at 51.89 is Neutral, neither overbought nor oversold. The STOCH value of 59.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ANAB.
AnaptysBio Risk Analysis
AnaptysBio disclosed 49 risk factors in its most recent earnings report. AnaptysBio reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AnaptysBio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $1.43B | 19.16 | 284.38% | ― | 948.35% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.73B | -66.67 | 442.91% | ― | 107.73% | 82.33% | |
49 Neutral | $231.58M | -3.01 | -21.40% | ― | -93.55% | -1143.58% | |
45 Neutral | $455.62M | -5.86 | -38.71% | ― | ― | 10.44% | |
45 Neutral | $954.60M | -5.12 | -48.22% | ― | ― | -10.16% |
* Healthcare Sector Average
ANAB
AnaptysBio
58.00
44.58
332.26%
MGTX
Meiragtx Holdings
14.56
7.07
94.39%
KROS
Keros Therapeutics
11.12
-4.13
-27.08%
CMPX
Compass Therapeutics
2.43
-1.06
-30.37%
OLMA
Olema Pharmaceuticals
10.85
5.33
96.56%
AnaptysBio Corporate Events
Executive/Board ChangesShareholder Meetings
AnaptysBio Shareholders Back Board, Governance and Incentives
Positive
Aug 11, 2026
On August 11, 2026, AnaptysBio, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected Class III directors Hollings Renton and John P. Schmid to three-year terms extending to the 2029 Annual Meeting. The voting results showe...
Business Operations and StrategyLegal Proceedings
AnaptysBio Enters Key Post-Trial Phase in Tesaro Dispute
Neutral
Jul 30, 2026
In November 2025, AnaptysBio filed a Verified Complaint in the Delaware Court of Chancery alleging that Tesaro materially breached their Collaboration and Exclusive License Agreement and that GlaxoSmithKline, Tesaro’s corporate parent, torti...
Business Operations and Strategy
AnaptysBio Subleases San Diego Facility to First Tracks
Neutral
Jun 22, 2026
On June 15, 2026, AnaptysBio entered into a sublease agreement with First Tracks Biotherapeutics to sublease approximately 45,057 rentable square feet of its San Diego premises at 10770 Wateridge Circle for an initial term of 12 months. The arrang...
DividendsRegulatory Filings and Compliance
AnaptysBio Details Tax Treatment of Spin-Off Dividend
Neutral
May 29, 2026
AnaptysBio, Inc. has filed IRS Form 8937 and plans to make the related information available on its website to explain the dividend received by stockholders from the separation and spin-off of First Tracks Biotherapeutics, Inc. The filing outlines...
Business Operations and StrategyRegulatory Filings and Compliance
AnaptysBio Adjusts Fiscal Year-End and Reporting Calendar
Neutral
May 21, 2026
On May 18, 2026, AnaptysBio, Inc.’s board of directors approved a shift in the company’s fiscal year-end from December 31 to June 30, with the next fiscal year set to begin on July 1, 2026. The company will file a transition Form 10-KT...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.